GlassScriptPhysician profile
Yevgeniy Isayev
NPI 1518975077
$2,394.24
in general payments reported to CMS, 2019-2025
16 companies · $53.07 in 2025
The $53.07 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $930 · 2020: $67.27 · 2021: $225 · 2022: $885 · 2023: $13.60 · 2024: $220 · 2025: $53.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $286.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $386.79 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $303.74 | 2021-2022 | |
| Genentech USA, INC. | $254.60 | 2019 | |
| Amgen INC. | $239.73 | 2019-2022 | |
| Viz.Ai, INC. | $213.46 | 2022 | |
| Abbvie INC. | $157.56 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $139.47 | 2022 | |
| Portola Pharmaceuticals, LLC | $124.80 | 2019 | |
| Novo Nordisk INC | $119.95 | 2019 | |
| Esperion Therapeutics, INC. | $108.05 | 2022 | |
| Acorda Therapeutics, INC | $100.75 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $99.62 | 2022 | |
| Lundbeck LLC | $95.05 | 2024 | Vyepti |
| Revance Therapeutics, INC. | $37.07 | 2025 | Daxxify |
| Pfizer INC. | $13.60 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yevgeniy Isayev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.